The SHS V fund managed by Tübingen-based SHS Gesellschaft für Beteiligungsmanagement has acquired a joint stake in Swiss evitria AG together with AFINUM. The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. For SHS, it is the first investment from its SHS V fund, which had its first […]

With a long tradition and as one of the largest hospitals in Germany, Olgahospital (“Olgäle”) focuses on treating sick children and young people. “Olgäle-Stiftung für das kranke Kind e. V.” (Olgäle foundation for sick children) was founded 20 years ago under the patronage of Carl, Duke of Württemberg. The foundation strives to ensure permanent aid […]

The Zollernalb-Tübingen Regional Group of Mukoviszidose e.V. is a self-help group consisting of 35 parents whose children suffer from cystic fibrosis. This incurable metabolic disease leads to a significant reduction in life expectancy. The cause of the disease is a gene mutation. Every 20th person in Germany carries the defective gene. Only if both parents […]

SHS Gesellschaft fuer Beteiligungsmanagement, MBG Baden-Württemberg and VC Fonds BW announced that Emerging Implant Technologies GmbH (EIT), a manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, has been acquired by Johnson & Johnson Medical GmbH. SHS became EIT’s lead investor in September 2016. Since then the Tuebingen based medtech specialist has subsequently supported […]

Digitization in the healthcare industry is progressing only very slowly due to the high density of regulation and complex development procedures. SHS will now invest its fifth fund (planned volume: EUR 150 million) in digital health companies for the first time. SHS Managing Partner Hubertus Leonhardt outlines the particular difficulties involved in investing in medical […]

The financing of new products in the health care industry is often difficult in Germany, as there is a lack of capital. The SHS Beteiligungsgesellschaft is now providing new capital, at least for some of the inventors: In the so-called First Closing, SHS has received commitments for more than 90 million euros from investors in […]

SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over €90 million in its fifth fund’s first closing. The Tuebingen-based medical technology investor has thus reached almost two thirds of its target of €150 million faster than expected. The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, […]

In mid-June the SHS portfolio company Novo announced the acquisition of Innocath. The Duisburg-based company specializes in the care of ventilated patients. Novo Klinik-Service, based in Bergheim, North Rhine-Westphalia, distributes medical equipment and medical technology solutions for intensive care, anaesthesia and nursing.

The start-up company CoreMedic has for the first time used its minimally invasive repair kits for the treatment of herniated valve diseases in a human operation. The operation was successful. SHS only acquired a stake in the company in 2017 with the aim of further developing the product.

The SHS portfolio company phenox, a strongly growing company in the field of neurointerventional stroke treatment, was portrayed by the WAZ. The company receives a grant of EUR 2.1 million from the Federal Ministry of Education and Research (BMBF) for its “anti-thrombosis” technology. This supports the development of coated implants for the treatment of brain […]

The article portrays the SHS portfolio company numares and provides insights into the company’s development and product portfolio. numares develops and sells diagnostic test systems and focuses on nuclear magnetic resonance (NMR) spectroscopy, machine learning and artificial intelligence.

© All rights reserved. Frankfurter Allgemeine Zeitung GmbH, Frankfurt. Provided by the Frankfurter Allgemeine Archiv SHS partner Dr. André Zimmermann reports in an interview with the FAZ on the new medical technology fund of SHS, which like its successful predecessor fund aims to invest in innovative life science companies in German-speaking countries and now also […]